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HECT E3 Ubiquitin Ligase HECW2 & Ubiquitylation
 The HECW2 ubiquitin ligase, a part of the NEDD4 family of HECT E3 Ubiquitin Ligases has several implications in disease as it is pre-
sumed to mediate ubiquitylation in a variety of cellular pathways. HECW2 plays a key part in regulation of the cell cycle by interacting 
with p73 to control apoptosis. HECW2 also controls the degradation of different nuclear proteins, such as Lamina A/C and PCNA, in-
volved in the formation and function of the nuclear lamina that provide the nucleus with structural integrity and stability. Dysfunction in 
HECW2 as a regulator of lamina formation is linked to Hutchinson-Gilford Progeria Syndrome. Downregulation of the HECW2 Ligase in 
other similar cellular pathways is implicated in the onset of rather different diseases, including Hirschprungʼs Disease, epilepsy, amyo-
trophic lateral sclerosis, muscular dystrophy, neurodegenerative disease, and neurodevelopmental delays. Structural and functional char-
acterization of this protein can give insight to the mechanisms of how these diseases may arise, thus giving a potential therapeutic target 
for these irreparable conditions.
  Mutations in the gene encoding for superoxide dismutase (SOD1),  an enzyme that breaks down potentially harmful oxygen molecules 
in the cell.  are found to have implications with the onset of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, causing loss 
of motor neurons in the spinal cord, brain stem, and motor cortex which often leads to paralysis and death. Previous studies show that 
HECW1 (also known as NEDL1), a close relative of HECW2, targets the mutant SOD for degradation but not the wild-type SOD. As 
HECW1 is so similar in structure to HECW2, current lab work aims to structurally characterize HECW2 and future lab goals aim to analyze 




















































His-Tag Nickel Affinity Column Chromatography
Future Plans 
HECW2 HECT Domain 1178 Extension HECW2 HECT Domain 1190 Extension HECW2 C-Lobe Domain 
Figure 2: HECW2 full length protein is 176 kDa shown through linear structure schematic (left). Residues 57-152 show the N-terminal 
domain and 172-282 show the C2 domain. Both WW domains are at residues 807 and 1018 with the WW-linker domain connecting to the  
N-lobe of the HECT domain. Full HECT domain is from residues 1237-1572, with C-lobe containing catalytic cysteine on the C-terminal end 
of the full length protein. Only NMR solution structure of HECW2 N-terminal domain solved of HECW2 by the Northeast Structural Genom-
ics Consortium available from PDB and visualized using biorender shows structural secondary fold of N-terminal domain. Many aspects of 
structural and function characteristics of the HECW2 Ubiquitin Ligase remain a mystery.
Figure 1: Ubiquitylation signalling pathway showing transfer of ubiquitin to targeted substrate via a 3 enzyme cascade, where the final 
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Figure 3: Current lab work aims to purify the HECW2 C-lobe and one of two HECW2 HECT-domain extensions show in protein purifica-
tion schematic (left). The HECW2 C-lobe vector uses a His-TEV tag which is cleaved with TEV protease (right) and vectors coding for the 
HECT-domain include extensions of secondary structures and a His-TEV to increase solubility.
 Figure 4: SDS-PAGE gels showing the HECW2 HECT-domain extensions have poor solubility, making it difficult to successfully purify. Re-
sults suggest that future purifications should omit cleavage of the His-SUMO tag or shorten dialysis time to keep protein soluble. Higher 
concentrations of protease or protease inhibitors and adjustments to the pH of buffers can also help prevent precipitation. Loss of protein 
during dialysis can be seen in lanes with no bands, while successful purification of C-lobe domain shows strong elution band at ~15 kDa. 
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•Successful purification of C-lobe and full-length HECT 
•Growth in M9 labeled media: NMR Spectroscopy of C-lobe
•C-lobe X-ray Crystallography trials 
•Vector design for WW domain and WW-linker domain
•Plasmid design for SOD-1 and SOD-G93A mutants
•Activitiy assays: 
 Ubiquitin interactions with full-length HECT domain and C-lobe 
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